Effect of antiretroviral therapy on the quality of patient's life

HIV and AIDS Review

Volumn 4, Issue 4, 2005, Pages 35-41

  Cholewińska, Grazyna ^a  

^a SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

Author keywords

HAART Influence on QoL; Health related quality of life (HRQoL); Quality of life (QoL)

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; INSULIN; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CACHEXIA; CARDIOVASCULAR SYMPTOM; COGNITIVE DEFECT; CULTURAL FACTOR; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIET RESTRICTION; DISABILITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DYSLIPIDEMIA; EMOTIONALITY; EXPECTATION; HEALTH STATUS; HEMATOLOGIC DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSURANCE; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIPOMATOSIS; LIVER TOXICITY; LONG TERM CARE; NAUSEA; NEUROPATHY; OPPORTUNISTIC INFECTION; PAIN; PARESTHESIA; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SELF CONCEPT; SEXUAL DYSFUNCTION; SOCIAL INTERACTION; SOCIAL PROBLEM; SOCIAL SUPPORT; SURVIVAL TIME; VOMITING; WEIGHT REDUCTION; WELLBEING;

EID: 33646436423     PISSN: 17301270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Karski J., Słońska Z., Wasilewski B.: Promocja Zdrowia. Sanmedia. Warszawa 1991.
2. Lohr K.N., et al.: Evaluating quality of life and health status instruments development of scientific review criteria. Clin.Ther. 1996.
3. Testa M., Simonson D. C.: Assessment of quality of life outcomes. N. Engl. J Med. 1996.
4. Carriri P., Spire B., Duran S., et al.: Health-Related Quality of Life After One Year of Higly Active Antiretroviral Therapy. J Acquir Immune Deffic Syndr 32(1), 2003.
5. Grossman H. A., Sullivan P., P., Albert W.: Quality of life and HIV: Current Assessment Tools and Future Directions for Clinical Practice. AIDS Read 13 (12), 2003.
6. Weinstain M.,C., Stason WB.: Hypertension. A policy Perspective. Harvard Univers. Press Cambridge 1976.
7. Hyland M., Kenyon C.: A scale for assessing quality of life. J. Psychometr. Res. 1991.
8. Douaihy A., Singh N.: Factors Affecting QOL in Patients with HIV Infection. AIDS Read. 11 (9) 2001
9. nd International HIV/AIDS Colloquium. Guadalajara. Mexico. 2000.
10. Scott J.D.: Simplifying the Treatment of HIV Infection with Ritonavir-Boosted Protease inhibitors in Antiretroviral - Experienced Patients. Am J Health-Syst Pharm. 2005. American Society of Health - System Pharmacists, 2005
11. MacManus S., Yates P., Elsron R, et al.: GW 433908/r Once -daily in antiretroviral naive HIV infected subjects. AIDS, 2004; 18: 651-655.
12. th Conference on Retroviruses and Opportunistic Infections. February 2005, Boston.
13. Penzak S.R, Chuck S.K.: Hyperlipidemia associated with HIV protease inhibitors use: pathophylosiology, prevalence, risk factors and treatment Scand J Infect Dis 2000; 22: 54-9.